The therapeutic responses of many solid tumours to chemo-and radio-therapies are far from
fully effective but therapies targeting malignancy-related cellular changes show promise for …

Purpose The clinical outcome of head and neck squamous cell carcinoma (HNSCC)
remains poor, partly due to the presence of resistant cancer stem cells (CSCs) which are …

Head and neck cancer (HNC) is the sixth most common cancer worldwide and show low
survival rates and drug resistance, which can be due to the presence of cancer stem cells …

Background Epidermal growth factor receptor (EGFR) is frequently amplified or
overexpressed in head and neck squamous cell carcinoma (HNSCC) and is a clinically …

Emerging data suggest that cancer stem cells (CSCs) exist in equilibrium with differentiated
cells and that stochastic transitions between these states can account for tumor …

The epidermal growth factor receptor (EGFR) is overexpressed in approximately 90% of
head and neck squamous cell carcinomas (HNSCC), and molecularly targeted therapy …

Members of the EGFR/ErbB family of tyrosine kinases are found to be highly expressed and
deregulated in many cancers, including head and neck squamous cell carcinoma (HNSCC) …

Objectives Cetuximab is an epidermal growth factor receptor (EGFR)-targeting drug that has
shown effects in head and neck squamous cell carcinoma (HNSCC). The effects are …

Cancer stem cells (CSCs) are a unique population of cells found within tumors that are able
to self-renew, restore the original heterogeneity of a tumor following treatment, and show …

Cetuximab, a specific anti-epidermal growth factor receptor (EGFR) monoclonal antibody, is
used in cancer treatment. Although development of resistance to cetuximab is well …